Introduction to a Dynamic Collaboration
Abzena, recognized as a leader in the integrated contract development and manufacturing organization (CDMO) for complex biologics, and Mabqi, a biotechnology innovator specializing in fully human antibodies, have entered a transformative strategic partnership.
Enhanced Drug Development Services
This strategic alliance is set to merge Mabqi's cutting-edge antibody discovery methodologies with Abzena's extensive development and manufacturing services. Together, they aim to provide biopharma customers with a comprehensive and efficient drug development pathway.
Addressing Key Development Challenges
By understanding the hurdles faced in early-stage drug development, the partnership seeks to offer a cohesive solution. This will enable drug developers to transition smoothly from the discovery phase through to pre-clinical development, addressing essential problems that often emerge in the timeline.
Innovative Methodologies for Success
The combined offerings leverage Mabqi's LiteMab Antibody Discovery Studio, which emphasizes hit screening and selection using advanced libraries. This strategic approach identifies top lead candidates efficiently, and integrates Abzena's strengths in cell line development, process development, and GMP manufacturing.
Expert Insights from Leadership
Campbell Bunce, Chief Scientific Officer at Abzena, emphasized that this partnership brings together two organizations rich in scientific expertise, aiming to speed up the drug discovery process. He noted the importance of leveraging data to reduce risks early in development, ultimately enhancing the success of clinical projects.
Shared Vision for Innovation
Sylvain Yon, CEO of Mabqi, remarked on the significance of this partnership, highlighting the exceptional synergy between their teams as a key aspect of their collaboration. Their focus on innovative technology and patient-centric approaches is expected to lead to the development of differentiated therapeutic antibodies that can significantly benefit patients globally.
About Abzena
Abzena specializes in providing a comprehensive range of services throughout the lifecycle of complex biologics, from initial discovery to commercial launch. They implement innovative strategies tailored to the unique needs of each project, allowing biotech and biopharma organizations to maximize the potential of their molecules.
About Mabqi
Mabqi is committed to advancing the discovery and development of fully human antibodies. They utilize an innovative platform specializing in monoclonal antibodies, antibody-drug conjugates, and various immunotherapy formats, all aimed at addressing unmet medical needs.
Frequently Asked Questions
1. What is the focus of the partnership between Abzena and Mabqi?
The partnership focuses on integrating Mabqi's antibody discovery capabilities with Abzena's development and manufacturing services to streamline drug development processes.
2. How will this partnership benefit biopharma companies?
Biopharma companies will benefit from a more seamless transition through the drug development stages, combined scientific support, and reduced timelines.
3. What services does Abzena offer?
Abzena offers end-to-end services for biologics, including process development, cell line development, and GMP manufacturing.
4. What are Mabqi's areas of expertise?
Mabqi specializes in discovering and developing fully human antibodies, including monoclonal antibodies and ADCs.
5. How does this partnership aim to impact patients?
The partnership aims to accelerate the development of innovative therapeutic antibodies that can make a significant difference in patient care.
